Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.

Journal of medical virology - 1 Dec 2001

Zöllner B, Schäfer P, Feucht H H, Schröter M, Petersen J, Laufs R

Abstract excerpt

It remains unclear whether sequential assessment of hepatitis B virus (HBV) load during lamivudine therapy can predict the loss of hepatitis B e antigen or emergence of drug-resistant variants. Therefore, a longitudinal study was carried out in 28 consecutive patients with chronic hepatitis B who started lamivudine therapy for a median of 12 months (range, 6-31). HBV DNA copy numbers were determined at 3-month...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Share to Viral Load

Source

Identifiers

PMID: 11745928
DOI: 10.1002/jmv.2087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy.PMID 11745928Read ↗

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.Semantic proximity Read ↗

Dynamics of Hepatitis B Virus Resistance to LamivudineSemantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

Quantitative hepatitis B virus DNA testing for the early prediction of the maintenance of response during lamivudine therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.Semantic proximity Read ↗

Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Semantic proximity Read ↗

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Semantic proximity Read ↗

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.Semantic proximity Read ↗

Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.